Department of Biomedical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan 46252, Korea.
Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju 26493, Gangwon, Korea.
Medicina (Kaunas). 2020 Jul 9;56(7):340. doi: 10.3390/medicina56070340.
: Breast cancer is the most common cancer among women worldwide. Early stage diagnosis is important for predicting increases in treatment success rates and decreases in patient mortality. Recently, circulating biomarkers such as circulating tumor cells, circulating tumor DNA, exosomes, and circulating microRNAs have been examined as blood-based markers for the diagnosis of breast cancer. Although has been studied for its function or expression in breast cancer, its potential diagnostic value in a clinical setting remains elusive and has not been investigated in South Korea. In this study, we aimed to evaluate the diagnostic utility of in plasma samples of breast cancer patients in South Korea. We investigated expression in the plasma of 30 breast cancer patients during diagnosis along with 30 healthy controls in South Korea by quantitative reverse transcription PCR. The results showed that circulating levels were significantly elevated in the breast cancer patients compared with those in healthy controls ( < 0.001). The sensitivity and specificity of circulating were 90.0% and 93.0%, respectively. Additionally, circulating showed high positivity at early stage. The positive rate of was as follows: 100% (10/10) for stage I, 90% (9/10) for stage II, and 80% (8/10) for stage III. was also a predictor of a 9.6-fold high risk for breast cancer ( < 0.001). Additional alternative molecular biomarkers for diagnosis and management of pre-cancer patients are needed. Circulating might be potential diagnostic tool for detecting early stage breast cancer.
乳腺癌是全世界女性最常见的癌症。早期诊断对于提高治疗成功率和降低患者死亡率至关重要。最近，循环生物标志物如循环肿瘤细胞、循环肿瘤 DNA、外泌体和循环 microRNAs 已被作为乳腺癌的血液标志物进行研究。尽管 在乳腺癌中的功能或表达已被研究，但在临床环境中的潜在诊断价值仍不清楚，并且在韩国尚未进行研究。在本研究中，我们旨在评估 在韩国乳腺癌患者血浆样本中的诊断效用。我们通过定量逆转录 PCR 研究了 30 名韩国乳腺癌患者和 30 名健康对照者在诊断期间血浆中的 表达。结果表明，与健康对照组相比，乳腺癌患者的循环 水平显著升高（ < 0.001）。循环 的灵敏度和特异性分别为 90.0%和 93.0%。此外，循环 在早期阶段表现出高阳性率。 的阳性率如下：I 期为 100%（10/10），II 期为 90%（9/10），III 期为 80%（8/10）。 也是乳腺癌 9.6 倍高风险的预测因子（ < 0.001）。需要寻找其他替代的分子生物标志物用于癌症前患者的诊断和管理。循环 可能是检测早期乳腺癌的潜在诊断工具。
